Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Nanexa AB holds a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently shows 1 pending office action. This single matter is assigned to 1 distinct examiner, reflecting a very specific and limited scope of current prosecution activity. This focused interaction suggests that the company's current intellectual property efforts are channeled through a single administrative path within the patent office, which may allow for a consistent prosecution strategy.
The activity is situated within 1 distinct art unit, which aligns with the specialized nature of the biotechnology field. Jennifer A Berrios is the busiest examiner for the portfolio, responsible for the 1 busiest examiner pending office action. The data indicates that the entirety of Nanexa AB's current pending patent office interactions is channeled through this one individual. This structure provides a singular point of contact for the company's pharmaceutical and biotechnological intellectual property matters, requiring the practitioner to focus their advocacy on the specific preferences and tendencies of this one examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERRIOS, JENNIFER A | 1 | 37.1% | +49.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18717160 | NEW INJECTABLE COMBINATION FORMULATION | BERRIOS, JENNIFER A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18717160 | NEW INJECTABLE COMBINATION FORMULATION | BERRIOS, JENNIFER A | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18717160 | NEW INJECTABLE COMBINATION FORMULATION | BERRIOS, JENNIFER A | 1613 | §103§112 | Non-Final OA | — | Pending | Jun 06, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNanexa AB has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jennifer A Berrios has the most, with 1 of Nanexa AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
